ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 28

Novel Ex Vivo Model of Septic Arthritis Identifies Role of Neutrophils in Joint Destruction

Kathryn McCall1, Caroline Atherton 2, Neal Millar 2, Carl Goodyear 3, Tom Evans 4 and Iain McInnes 2, 1Institute of Infection, Immunity & Inflammation, University of Glasgow, Galsgow, United Kingdom, 2Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, 3University of Glasgow, Glasgow, United Kingdom, 4Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: arthritis and bacterial infections, cartilage, neutrophils, septic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Innate Immunity Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Septic arthritis (SA) caused by bacterial species, such as Staphylococcus aureus, has high morbidity and mortality1. Currently diagnosis is often prolonged and unreliable, with no suitable near-patient biomarkers available2. To generate more reliable biomarkers and to understand pathogenesis we sought to develop a novel ex vivo system to explore the effect of pathogenic and mutant Staphylococcus strains in promoting cartilage degradation.

Methods: Human cartilage explants were obtained from femoral heads being surgically removed following trauma. Explants were infected for 48h with 106 cfu bacteria from two Staph. aureus SA-derived patient isolates (28g & 36v) or with a mutated bacterial strain preventing biofilm formation and adhesion, Staphylococcus epidermidis RP62A wild type strain or RP62A mutated strain. In the final 24h of bacterial infection, neutrophils purified from healthy donor blood were added to explant cultures at 3 x 106 cells/well. Chondrocyte viability was assessed using CellTracker green CMFDA and propidium iodide. Images were captured using confocal microscopy (LSM880) and cells counted using Imaris software. Structural damage was measured by glycosaminoglycan (GAG) release and statistical analysis performed using GraphPad Prism software.

Results: When cartilage explants were co-cultured with bacteria +/- neutrophils, cell death was significantly increased compared to the negative control or addition of neutrophils alone, (one-way ANOVA, Holm-Sidak’s multiple comparisons test, N=3, bacteria – neutrophils p < 0.05, bacteria + neutrophils p < 0.01). Cartilage breakdown, estimated via GAG release, was induced by Staph. aureus alone, whereas it was significantly enhanced upon neutrophil addition in the final 24h of co-culture, Figure 1. Using the model, we investigated the effect of bacterial cell adhesion using a Staph. epidermidis adhesion mutant. The mutated strain did not significantly release more GAG compared to the negative control, whereas the wild type strain caused significant damage (2-way ANOVA, Holm-Sidak’s multiple comparisons test, N=3, p < 0.05). Moreover, the effect of neutrophil stimulation was attenuated when bacteria were unable to adhere to the cartilage.

Conclusion: A co-culture model of septic arthritis has been developed which allows precise examination of the contribution of the host neutrophil response and (mutant) bacterial species to cartilage damage. We used this to define the importance of bacterial adherence to cartilage for subsequent degradation. This novel model will be a valuable tool in understanding pathology and identifying biomarkers of joint infection in the future.

References

  1. Gupta, M. N., Sturrock, R. D. & Field, M. A prospective 2-year study of 75 patients with adult-onset septic arthritis. Rheumatology40, 24–30 (2001).
  2. Swan, A., Amer, H. & Dieppe, P. The value of synovial fluid assays in the diagnosis of joint disease: a literature survey. Ann. Rheum. Dis.61, 493–8 (2002).

Figure 1. Cartilage damage measured by % GAG release upon infection with Staph. aureus SA-derived patient isolates -28g & 36v-, +/- neutrophil stimulation. One-way ANOVA, Holm-Sidak’s multiple comparison test, N=6, ** p < 0.01, p *** 0.001.


Disclosure: K. McCall, None; C. Atherton, None; N. Millar, Novartis, 2, 5, 8; C. Goodyear, Celgene, 2, AstraZeneca, 2, 5, MedAnnex, 2, 5, UCB, 2, Jannsen, 2; T. Evans, None; I. McInnes, Abbott, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Roche., 2, 8, Abbvie, 5, AbbVie, 2, 5, 8, Amgen, 2, 5, 8, Astra Zeneca, 2, 5, AstraZeneca, 5, BI, 2, 5, BMS, 2, 5, 8, Boehringer Ingelheim, 5, Celgene, 2, 5, 8, Eli Lilly, 2, 5, 8, Janssen, 2, 5, 8, Leo, 5, Lilly, 5, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, UCB, 2, 5, 8.

To cite this abstract in AMA style:

McCall K, Atherton C, Millar N, Goodyear C, Evans T, McInnes I. Novel Ex Vivo Model of Septic Arthritis Identifies Role of Neutrophils in Joint Destruction [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/novel-ex-vivo-model-of-septic-arthritis-identifies-role-of-neutrophils-in-joint-destruction/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/novel-ex-vivo-model-of-septic-arthritis-identifies-role-of-neutrophils-in-joint-destruction/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology